ARS Pharmaceuticals had its Relative Strength (RS) Rating upgraded from 86 to 95 Friday.
IBD's unique rating tracks price action with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the last 52 weeks compares to all the other stocks in our database.
History shows that the top-performing stocks tend to have an 80 or higher RS Rating in the early stages of their moves.
Looking For The Best Stocks To Buy And Watch? Start Here
ARS Pharmaceuticals is not currently near a potential buy zone. See if the stock goes on to build a chart pattern that could kick off a new price move.
ARS Pharmaceuticals posted 0% EPS growth in the latest quarterly report, while sales growth came in at 4,900%.
ARS Pharmaceuticals earns the No. 51 rank among its peers in the Medical-Biomed/Biotech industry group. Krystal Biotech, ADMA Biologics and Catalyst Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
